RUA Life Sciences PLC Director/PDMR Shareholding (7234J)
December 14 2022 - 8:04AM
UK Regulatory
TIDMRUA
RNS Number : 7234J
RUA Life Sciences PLC
14 December 2022
14 December 2022
RUA Life Sciences Plc
("RUA Life Sciences", the "Company" or the "Group")
Director Dealing
RUA Life Sciences, the holding company of a group of medical
device businesses focused on the exploitation of the patented
long-term implantable biostable polymer, Elast-Eon(TM) , announces
that it was notified on 14 December 2022 that Lachlan Smith, Chief
Financial Officer, purchased 19,341 ordinary shares in the Company
at 54.2p on 14 December 2022.
Following the purchase, Lachlan Smith owns 19,341 ordinary
shares of the Company.
For further information contact:
RUA Life Sciences
Bill Brown, Chairman Tel: +44 (0)1294 317073
Caroline Stretton, Group Managing Director Tel: +44 (0)1294
317073
Cenkos Securities plc (Nominated Adviser and Broker) Tel: +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael Johnson (Sales)
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Lachlan Smith via SIPP
------------------------------------------- ----------------------------
2. Reason for the notification
-------------------------------------------------------------------------
a) Position/status: Chief Financial Officer
------------------------------------------- ----------------------------
b) Initial notification/Amendment: Initial notification
------------------------------------------- ----------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name: RUA Life Sciences plc
------------------------------------------- ----------------------------
b) LEI: 213800BMVB22PVOJ9Z28
------------------------------------------- ----------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of the financial instrument, Ordinary Shares of 5 pence
type of instrument: GB0033360586
Identification code:
------------------------------------------- ----------------------------
b) Nature of the transaction: Purchase of Ordinary Shares
------------------------------------------- ----------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
54.17p 19,341
------------------------------------------- ----------------------------
d) Aggregated information:
-- Aggregated volume: n/a
-- Price:
------------------------------------------- ----------------------------
e) Date of the transaction: 14 December 2022
------------------------------------------- ----------------------------
f) Place of the transaction: London Stock Exchange
------------------------------------------- ----------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFFDFDLEESESE
(END) Dow Jones Newswires
December 14, 2022 08:04 ET (13:04 GMT)
Aortech (LSE:AOR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Aortech (LSE:AOR)
Historical Stock Chart
From Aug 2023 to Aug 2024